These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38516690)

  • 1. Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy.
    Yonezawa Ogusuku IE; Herbel V; Lennartz S; Brandes C; Argiro E; Fabian C; Hauck C; Hoogstraten C; Veld S; Hageman L; Teppert K; Koutsoumpli G; Griffioen M; Mockel-Tenbrinck N; Schaser T; de Groot R; Johnston ICD; Lock D
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101224. PubMed ID: 38516690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
    van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
    J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
    van der Lee DI; Koutsoumpli G; Reijmers RM; Honders MW; de Jong RCM; Remst DFG; Wachsmann TLA; Hagedoorn RS; Franken KLMC; Kester MGD; Harber KJ; Roelofsen LM; Schouten AM; Mulder A; Drijfhout JW; Veelken H; van Veelen PA; Heemskerk MHM; Falkenburg JHF; Griffioen M
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated, scaled, transposon-based production of CAR T cells.
    Lock D; Monjezi R; Brandes C; Bates S; Lennartz S; Teppert K; Gehrke L; Karasakalidou-Seidt R; Lukic T; Schmeer M; Schleef M; Werchau N; Eyrich M; Assenmacher M; Kaiser A; Prommersberger S; Schaser T; Hudecek M
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.
    Dong H; Ham JD; Hu G; Xie G; Vergara J; Liang Y; Ali A; Tarannum M; Donner H; Baginska J; Abdulhamid Y; Dinh K; Soiffer RJ; Ritz J; Glimcher LH; Chen J; Romee R
    Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122379119. PubMed ID: 35696582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
    Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
    Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular therapy against public neoantigens.
    Armistead PM
    J Clin Invest; 2019 Feb; 129(2):506-508. PubMed ID: 30640175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.
    Lock D; Mockel-Tenbrinck N; Drechsel K; Barth C; Mauer D; Schaser T; Kolbe C; Al Rawashdeh W; Brauner J; Hardt O; Pflug N; Holtick U; Borchmann P; Assenmacher M; Kaiser A
    Hum Gene Ther; 2017 Oct; 28(10):914-925. PubMed ID: 28847167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.
    Forghieri F; Riva G; Lagreca I; Barozzi P; Bettelli F; Paolini A; Nasillo V; Lusenti B; Pioli V; Giusti D; Gilioli A; Colasante C; Galassi L; Catellani H; Donatelli F; Talami A; Maffei R; Martinelli S; Potenza L; Marasca R; Tagliafico E; Manfredini R; Trenti T; Comoli P; Luppi M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control.
    Cai Y; Prochazkova M; Jiang C; Song HW; Jin J; Moses L; Gkitsas N; Somerville RP; Highfill SL; Panch S; Stroncek DF; Jin P
    J Transl Med; 2021 Dec; 19(1):523. PubMed ID: 34952597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1
    De Cicco M; Lagreca I; Basso S; Barozzi P; Muscianisi S; Bianco A; Riva G; Di Vincenzo S; Pulvirenti C; Sapuppo D; Siciliano M; Rosti V; Candoni A; Zecca M; Forghieri F; Luppi M; Comoli P
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules.
    Jin J; Gkitsas N; Fellowes VS; Ren J; Feldman SA; Hinrichs CS; Stroncek DF; Highfill SL
    J Transl Med; 2018 Jan; 16(1):13. PubMed ID: 29368612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia.
    Campillo-Davo D; Anguille S; Lion E
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Good manufacturing practice production of CD34
    de Jonge PKJD; van Hauten PMM; Janssen LD; de Goede AL; Berrien-Elliott MM; van der Meer JMR; Mousset CM; Roeven MWH; Foster M; Blijlevens N; Hobo W; Fehniger TA; Jansen JH; Schaap NPM; Dolstra H
    Cancer Immunol Immunother; 2023 Oct; 72(10):3323-3335. PubMed ID: 37477653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.
    Kang S; Li Y; Qiao J; Meng X; He Z; Gao X; Yu L
    Front Oncol; 2022; 12():787108. PubMed ID: 35356211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products.
    Silva DN; Chrobok M; Rovesti G; Healy K; Wagner AK; Maravelia P; Gatto F; Mazza M; Mazzotti L; Lohmann V; Sällberg Chen M; Sällberg M; Buggert M; Pasetto A
    Front Immunol; 2022; 13():896242. PubMed ID: 35784320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.